ACT Brief: AI and Wearables for Patient Monitoring, FDA Modernizes Evidence Standards, and Regulatory Alignment in Rare Disease

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part five of his video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, discussed how AI can address information overload by identifying trends in massive wearable data streams and separating true alarms from false ones. AI models that factor in patient history, lab data, and imaging can detect subtle patterns imperceptible to clinicians, such as speech changes predictive of heart failure exacerbations, enabling earlier intervention across multiple disease states.
• In a new FAQ article, we examined four FDA policy shifts reshaping drug development in early 2026: a single-trial standard supported by confirmatory evidence, a plausible mechanism framework for ultra-rare individualized therapies, validation principles for new approach methodologies as animal testing alternatives, and clearer guidance on Bayesian statistical methods. Collectively, these actions reflect FDA recalibration toward evidence quality and analytical sophistication over data volume, with particular value in rare disease and pediatric populations where traditional designs are inefficient.
• In a new interview from Pharmaceutical Executive, Laksheeta Johari, analyst for Lifescience Dynamics, addressed questions about FDA regulatory consistency in rare diseases. While guidelines promise flexibility for innovative development, recent CRLs raise doubts about how FDA applies those principles to actual trial designs and control arms. Sponsors cite misalignment between stated guidance and regulatory feedback, signaling a need for clearer communication during touchpoint meetings to ensure consistent implementation.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.